| Date | Time | Source | Announcement |
|---|---|---|---|
| 10 Feb 2016 | 07:00 AM | Notice of Preliminary Results | |
| 07 Jan 2016 | 07:00 AM | Top-line results from Japanese study of Traumakine | |
| 29 Dec 2015 | 07:00 AM | First Patient recruited in Phase III ARDS Study | |
| 21 Dec 2015 | 07:00 AM | Faron Awarded ?1.5 million Tekes Funding | |
| 30 Nov 2015 | 07:00 AM | Key Publication in Journal of Immunology | |
| 17 Nov 2015 | 07:30 AM | Admission to AIM and first day of dealings |
Faron Pharmaceuticals Oy is a Finland-based, clinical-stage biopharmaceutical company focused on developing innovative cancer treatments that leverage the patient's own immune system, with a lead asset, bexmarilimab, currently in Phase I/II clinical trials. Faron Pharmaceuticals is listed under the ticker FARN.
FARN share price launched at 230p in 2015.